UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Dan Johnson, PhD

Title(s)Professor, Otolaryngology
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Princeton UniversityPhD - Molecular Biology
    Princeton UniversityMA - Molecular Biology

    Collapse Overview 
    Collapse Overview
    Daniel Johnson, PhD, is Professor and Vice Chair of Research in the Department of Otolaryngology – Head and Neck Surgery (OHNS) at the University of California, San Francisco. He obtained a bachelor of science in chemistry and a bachelor of arts in mathematics, both from North Park University in Chicago, Illinois. Dr. Johnson earned his MA and PhD in molecular biology from Princeton University, followed by a postdoctoral fellowship at the University of California, San Francisco. Prior to joining UCSF Otolaryngology, Dr. Johnson was a Professor in the Division of Hematology/Oncology, Department of Medicine, and Department of Pharmacology and Chemical Biology at the University of Pittsburgh, Pennsylvania. Dr. Johnson was also the Scientific Director of the Acute Leukemia Working group at the University of Pittsburgh Cancer Institute.

    Dr. Johnson has published 68 original papers and 21 reviews and book chapters, and is Editor for the book entitled “Cell Death Signaling in Cancer Biology and Treatment”. He has maintained continuous NIH funding as a principal investigator since 1995, and has served as a standing member for both NIH and ACS study sections. Dr. Johnson continues to play an active role on multiple review panels for the NIH, VA, and other granting agencies. Since 2001 he has served as a Section Editor for Leukemia, the top-ranked journal for hematologic malignancies, and has also served as Editor for Cancer Research and Oncology Research. Dr. Johnson places a high priority on translating findings from his lab to the clinic, and has facilitated the development of clinical trials in both leukemia and head and neck cancer.

    Dr. Johnson greatly values teaching and serving as a mentor for individuals with a broad variety of educational backgrounds. He has served as primary mentor for 32 trainees in his lab. Most of his trainees have gone on to higher academic or clinical positions, including 10 who are now junior faculty at academic institutions. He was the first lab-based faculty to be awarded the G. David Roodman Excellence in Mentorship Award by the University of Pittsburgh Hematology/Oncology Clinical Fellows. At the University of Pittsburgh he also was a leader for the Career Mentoring Program for junior faculty, and taught extensively in both the graduate and medical schools.

    Head and Neck Oncology

    Molecular biology and molecular genetics of head and neck cancer, anti-cancer drug development

    Professional Interests:
    Development of new therapeutic strategies and agents for head and neck cancer, mechanisms of chemotherapy resistance, cell death mechanisms, mentoring

    Education and Training:
    • Graduate School: Princeton University, NJ – M.A., Molecular Biology
    • Graduate School: Princeton University, NJ – Ph.D., Molecular Biology
    • Postdoctoral Fellowship: University of California, San Francisco

    Awards and Honors:
    • 2015-present – Oncology Research Editorial Board
    • 2014 – G. David Roodman Excellence in Mentorship Award from Hematology/Oncology Fellows
    • 2010-2013 – Cancer Research Editorial Board
    • 2007 – Hillman Fellow for Innovative Cancer Research
    • 2001-present – Leukemia Section Editor
    • 1999-present – Leukemia Editorial Board
    • 1994-95 – Fellow of the Lymphoma Research Foundation of America
    • 1990 – Henry Christian Outstanding Abstract in Cardiology, AFCR
    • 1988-1992 – Fellow of the Cardiovascular Research Institute, UCSF
    • 1989 – American Heart Association Postdoctoral Fellowship
    • 1982 – Graduated summa cum laude, North Park College
    • 1981 – Walter E. Olson Memorial Scholarship Fund
    • 1981 – J. Paul Bennett Chemistry Award
    • 1980-82 – President, North Park University Mathematics Society
    • 1979 – Oscar E. Olson Memorial Scholarship Fund in Mathematics

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lee MJ, Jin N, Grandis JR, Johnson DE. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochim Biophys Acta Mol Cell Res. 2020 Jun; 1867(6):118679. PMID: 32061630.
      View in: PubMed
    2. O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS One. 2020; 15(1):e0227261. PMID: 31914141.
      View in: PubMed
    3. Lau YK, Ramaiyer M, Johnson DE, Grandis JR. Targeting STAT3 in Cancer with Nucleotide Therapeutics. Cancers (Basel). 2019 10 29; 11(11). PMID: 31671769.
      View in: PubMed
    4. Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE. Gene targets of sulforaphane in head and neck squamous cell carcinoma. Mol Med Rep. 2019 Dec; 20(6):5335-5344. PMID: 31661135.
      View in: PubMed
    5. Cai Y, Yousef A, Grandis JR, Johnson DE. NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. Adv Biol Regul. 2020 01; 75:100653. PMID: 31594701.
      View in: PubMed
    6. Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncol. 2019 08; 95:35-42. PMID: 31345392.
      View in: PubMed
    7. Sola AM, Johnson DE, Grandis JR. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opin Investig Drugs. 2019 04; 28(4):351-363. PMID: 30753792.
      View in: PubMed
    8. Lee YS, Johnson DE, Grandis JR. An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2018 12; 23(4):283-299. PMID: 30376740.
      View in: PubMed
    9. Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE. Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. Int J Mol Sci. 2018 May 30; 19(6). PMID: 29848966.
      View in: PubMed
    10. Santuray RT, Johnson DE, Grandis JR. New Therapies in Head and Neck Cancer. Trends Cancer. 2018 05; 4(5):385-396. PMID: 29709262.
      View in: PubMed
    11. Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2018 05 01; 78(9):2383-2395. PMID: 29440171.
      View in: PubMed
    12. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018 04; 15(4):234-248. PMID: 29405201.
      View in: PubMed
    13. Leonard BC, Johnson DE. Signaling by cell surface death receptors: Alterations in head and neck cancer. Adv Biol Regul. 2018 01; 67:170-178. PMID: 29066276.
      View in: PubMed
    14. Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017 09; 36(3):463-473. PMID: 28866730.
      View in: PubMed
    15. Johnson DE, Bauman JE. When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials. Cancer Prev Res (Phila). 2017 09; 10(9):489-490. PMID: 28821544.
      View in: PubMed
    16. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083. PMID: 27986750.
      View in: PubMed
    17. Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR. Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS One. 2016; 11(11):e0166185. PMID: 27855189.
      View in: PubMed
    18. Bhola NE, Johnson DE, Grandis JR. A sensible approach to targeting STAT3-mediated transcription. Ann Transl Med. 2016 Oct; 4(Suppl 1):S57. PMID: 27868025.
      View in: PubMed
    19. Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR. STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Aug; 9(8):657-63. PMID: 27267892.
      View in: PubMed